Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 2 Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects
jRCT2080222720Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of esaxerenone in essential hypertension (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in sitting blood pressure. Started Jan 2015; status: completed.
02
Drugs
esaxerenone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080222720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222720.